Why the study?
METS-IR and TyG-BMI were proposed as surrogate markers of insulin resistance and potential cardiovascular risk factors, but their predictive value for MACE and all-cause mortality in AMI patients was unclear.
Do METS-IR and TyG-BMI predict MACE and all-cause mortality in patients with acute myocardial infarction?
Do METS-IR and TyG-BMI predict MACE and all-cause mortality in patients with acute myocardial infarction?
METS-IR and TyG-BMI do not have predictive value for major adverse cardiovascular events in patients with acute myocardial infarction and should not be used for this purpose.
May enhance post-AMI risk stratification; leaves open incremental value over standard models.
BACKGROUND: Recently two indicators - metabolic score for insulin resistance (METS-IR) and triglyceride glucose-BMI (TyG-BMI) have been proposed as surrogate markers of IR and potential cardiovascular risk factors. The aim of the study was to assess the predictive value of METS-IR and TyG-BMI concerning the incidence of major adverse cardiovascular events (MACE) and all-cause mortality in 1-year follow-up among patients admitted with acute myocardial infarction (AMI). METHODS: Two thousand one hundred fifty-three patients with a median age of 68 years were enrolled in the study. Patients were divided into two groups according to the type of AMI. RESULTS: MACE occurred in 7.9% of the patients in the ST-segment elevation myocardial infarction (STEMI) group and in 10.9% of the non-STEMI (NSTEMI) group. No significant difference in median MACE-IR and TyG-BMI between patients with and without incidence of MACE was found in both groups. None of the examined indices were predictors of MACE in the STEMI and NSTEMI groups. Moreover, both of them did not predict MACE in subgroups of patients classified according to the presence of diabetes. Finally, METS-IR and TyG-BMI were significant predictors of 1-year morality, however with low prognostic value and only in univariate regression analysis. CONCLUSION: METS-IR and TyG-BMI should not be used in predicting MACE among patients with AMI.
No takes yet. Share an insight, caveat, or question.
Drwiła-Stec et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: